<DOC>
	<DOCNO>NCT01688947</DOCNO>
	<brief_summary>The primary objective study evaluate analgesic efficacy 2 dose level V116517 versus placebo .</brief_summary>
	<brief_title>Analgesic Efficacy Safety V116517 Subjects With Moderate Severe Chronic Pain Due Postherpetic Neuralgia ( PHN )</brief_title>
	<detailed_description />
	<mesh_term>Chronic Pain</mesh_term>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Neuralgia , Postherpetic</mesh_term>
	<mesh_term>Analgesics</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>Key 1 . Subjects chronic pain due PHN primary pain condition degree pain every day condition . 2 . Clinical diagnosis PHN base history painful dermatomal blister rash resolve week follow persistent pain region â‰¥ 3 month duration . Key 1 . Subjects chronic pain condition PHN predominant pain condition , include gout , pseudo gout , psoriatic arthritis , active Lyme disease , rheumatoid arthritis inflammatory arthritis , fibromyalgia , neuropathic pain condition , bursitis , acute injury sign active infection target pain area . 2 . Subjects agree stop concomitant analgesic medication apart specify protocol supplemental analgesic medication . 3 . Subjects recent history seizure within past 5 year . 4 . Subjects use opioids 4 day per week . 5 . Subjects clinically unstable medical condition , include cardiac disease ( unstable atrial fibrillation , symptomatic bradycardia , unstable congestive heart failure , active myocardial ischemia ) ; respiratory disease ; biliary tract disease ; hypothyroidism ; adrenal cortical insufficiency ; medical condition investigator 's opinion inadequately treat precludes entry study . 6 . Subjects history suicide attempt , subject clinically judge principal investigator ( PI ) serious risk suicide . 7 . PHNpainconditionspecific exclusion : Subjects receive paincontrol intervention include neurolytic block neurosurgical procedure affect nerve spinal cord segment , spinal cord , stimulators , neuraxial infusion pump . 8 . Activecomparatorrelated exclusion : Subjects allergic tolerate pregabalin acetaminophen . Other protocol specific inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Pain</keyword>
	<keyword>Neuralgia , Postherpetic</keyword>
</DOC>